Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ultibro

- PMLiVE

AstraZeneca blocks take-private buyout of Sobi

The $7.6bn takeover of Swedish rare disease company Sobi by private equity group Advent International and Singapore’s wealth fund failed to convince the 90% of shareholders needed

regeneron headquarters

Regeneron signs $900m cancer and infectious disease deal with Nykode

The deal with Norwegian clinical-stage vaccine specialist Nykode (previously Vaccibody) includes an upfront payment of $30m and an equity investment of $20m plus additional payments

- PMLiVE

AstraZeneca officially opens new R&D facility in UK

The high-tech £1bn research and development DISC facility in Cambridge, UK will see 2,000+ scientists housed in a building designed to the highest environmental standards

- PMLiVE

Gilead to pay $745m for three oncology programmes from Arcus Biosciences

The deal will enable Gilead to accelerate the development of candidate molecules and explore treatment combinations with long-term partner Arcus Biosciences

- PMLiVE

AstraZeneca/Moderna’s mRNA treatment for heart failure looks promising

The therapy – an mRNA-encoding vascular endothelial growth factor – looks promising for patients undergoing coronary artery bypass surgery

- PMLiVE

AstraZeneca signs for-profit agreements for its COVID-19 vaccine

The for-profit deals are aimed to ‘progressively transition the vaccine to modest profitability’ as COVID-19 moves from a pandemic to an endemic disease

- PMLiVE

Roche and Novartis part ways with share purchase

Novartis is to sell its one-third stake in Roche for more than $20bn, paving the way for potential acquisitions

- PMLiVE

Novartis invests $1.3bn in protein degradation technology

Novartis will work with UK-based start-up Dunad Therapeutics to develop protein degradation drugs

- PMLiVE

Novartis receives approval for third-generation leukaemia therapy

With a novel mechanism of action, Scemblix is a new option for people with chronic myeloid leukaemia who experience intolerance or inadequate response to standard therapy

- PMLiVE

Novartis sales top £13bn in Q3 as the company reviews its generic business Sandoz

The company has started a strategic review of Sandoz as sales drop 20% in ‘challenging’ US market

- PMLiVE

AZ’s Imfinzi boosts survival in biliary tract cancer

Positive results for Imfimzi plus chemotherapy offer hope for patients with a rare and aggressive gastrointestinal cancer

- PMLiVE

Valneva COVID-19 vaccine more effective than AZ

Valneva will seek regulatory approval in the UK and European Union after its COVID-19 vaccine candidate performed well in phase 3 trials

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links